Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

In short

This is a Research and Innovation Action under Horizon Europe. The budget is €24 million for about 3 grants of €7 million to €9 million each. It is paid as a lump sum, so you report results instead of costs. Submission opens on 10 February 2027. Deadline: 16 September 2027.

What the call wants to achieve

• Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities
• Researchers, physicians, innovators [1] , startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation
• National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare (…)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0, summarised. The official call text and its annexes decide eligibility, budget and deadlines.

Similar calls